Cameron S T, Melvin L, Glasier A, Scott G, Johnstone A, Young H
Dean Terrace Family Planning and Well Woman Services, NHS Lothian, Edinburgh, UK.
BJOG. 2007 Dec;114(12):1516-21. doi: 10.1111/j.1471-0528.2007.01506.x. Epub 2007 Sep 17.
To determine willingness of health professionals to adopt new interventions for treating sexual partners of women with chlamydia.
Anonymous, self-administered questionnaires of doctors, practice nurses and community pharmacists regarding novel testing/treatment options for partners of women with chlamydia.
Local (Scotland) and national (UK) clinical meetings in reproductive health, and community pharmacy (Lothian).
Doctors (general practice, gynaecology, family planning) and practice nurses who were delegates at selected meetings in reproductive health and community pharmacists attending pharmacy meetings.
Doctors and nurses were invited to complete a questionnaire indicating their preferred strategy for testing/treating sexual partners of women with chlamydia if given choice of partner notification, postal testing kit (PTK), patient delivered partner medication (PDPM) with azithromycin or combined PDPM and PTK. Community pharmacists were invited to complete a questionnaire regarding their willingness to introduce chlamydia testing and treatment services.
Reported preferences of doctors and nurses for partner testing/treatment strategies and willingness of pharmacists to offer new services.
Questionnaires were completed by 211 doctors, 73 practice nurses and 50 pharmacists. The most popular choice of doctors (30%) and nurses (23%) was a combination of PDPM with PTK, with partner notification the least popular (8 and 3%, respectively). One in four doctors had previously used PDPM for treating partners. Most pharmacists were willing to supply free PTKs (98%), offer testing (75%) and treatment services (100%) and give women PDPM for partners (80%).
Relevant health professionals, who are increasingly involved in managing chlamydia, are largely in favour of introducing new strategies for treating sexual partners.
确定卫生专业人员采用新干预措施治疗衣原体感染女性性伴侣的意愿。
针对医生、执业护士和社区药剂师进行匿名的自我管理问卷调查,内容涉及衣原体感染女性性伴侣的新型检测/治疗方案。
当地(苏格兰)和全国(英国)生殖健康临床会议以及社区药房(洛锡安)。
参加选定生殖健康会议的医生(全科、妇科、计划生育)和执业护士,以及参加药房会议的社区药剂师。
邀请医生和护士填写问卷,表明如果可选择伴侣通知、邮政检测试剂盒(PTK)、患者自行交付给伴侣的阿奇霉素药物(PDPM)或PDPM与PTK组合的方式,他们治疗衣原体感染女性性伴侣的首选策略。邀请社区药剂师填写关于他们引入衣原体检测和治疗服务意愿的问卷。
医生和护士报告的伴侣检测/治疗策略偏好以及药剂师提供新服务的意愿。
211名医生、73名执业护士和50名药剂师完成了问卷。医生(30%)和护士(23%)最常选择的是PDPM与PTK的组合,伴侣通知是最不受欢迎的选择(分别为8%和3%)。四分之一的医生此前曾使用PDPM治疗伴侣。大多数药剂师愿意提供免费PTK(98%)、提供检测(75%)和治疗服务(100%),并为女性提供给伴侣的PDPM(80%)。
越来越多地参与衣原体管理的相关卫生专业人员在很大程度上支持引入治疗性伴侣的新策略。